Business Wire

RELIEF THERAPEUTICS Holding SA Announces the Closing of its Share Exchange Agreement with Sonnet BioTherapeutics, Inc. for the Divestment of its wholly-owned Subsidiary Relief Therapeutics SA

Share

RELIEF THERAPEUTICS Holding SA (SIX:RLF, "Relief Holding") announces today the closing of the binding Share Exchange Agreement (“SEA”) for the acquisition by Sonnet BioTherapeutics, Inc. (“Sonnet”), now a subsidiary of Sonnet BioTherapeutics Holdings, Inc. (formerly known as Chanticleer Holdings, Inc.) (Nasdaq:SONN, "Sonnet Holdings") of Relief Therapeutics SA (“Relief SA”), a subsidiary of Relief Holding signed August 12, 2019. As a consequence, Sonnet acquires all outstanding shares of Relief SA that becomes a wholly-owned Geneva-based subsidiary of Sonnet. In counterpart, Sonnet paid to Relief Holding shares of its common stock that converted into 757,933 shares of listed Sonnet Holdings common stock. This number differs from the 7,111,947 shares originally announced as Sonnet shares were converted into Sonnet Holdings shares in its recent merger that closed on April 1, 2020 at a ratio of approximately 0.106572 Sonnet Holdings shares per Sonnet share, taking into account a reverse stock split effected by Sonnet Holdings immediately prior to the merger at the ratio of 26:1.

Sonnet is an oncology-focused biotechnology company developing targeted biologic drugs based on their innovative Fully Human Albumin Binding (“FHABTM”) platform. Together with its proprietary pipeline of preclinical-stage assets, Sonnet will pursue the funding of Atexakin Alfa acquired together with Relief SA. Atexakin Alfa is a low dose formulation of Interleukin-6 that has demonstrated efficacy in animal models of neuropathies (induced by diabetes or by chemotherapeutic treatment) as well as human safety in previous clinical trials. Sonnet is positioning Atexakin Alfa to rapidly enter clinical trial which aim is to confirm safety and tolerability as well as to provide preliminary insights into efficacy for CIPN.

This divestment will allow Relief Holding to focus its resources to further develop its main asset Aviptadil for pulmonary affections. In particular, Relief Holding’s utmost priority is to concentrate on the immediate clinical testing of Aviptadil for the consequences of COVID-19 affections, in particular Acute Respiratory Distress Syndrome (“ARDS”). Relief Holding through an active collaboration with NeuroRX was recently granted by the Food and Drug Administration (“FDA”) an IND “Study May Proceed” for the treatment of COVID-19-induced ARDS. Aviptadil may also be subsequently further developed for other lung diseases including Sarcoidosis and Acute Lung Injury for which preliminary clinical results are encouraging.

The closing of this agreement constitutes an amazing achievement at different levels. It will provide a solid opportunity for atexakin alfa to demonstrate in the clinic its therapeutic benefit, and, at the same time it brings significant resources and focus to Relief Holding to fund the development of its remaining asset Aviptadil. This is a unique opportunity to support the clinical development of two drugs with astonishing potential to positively transform the lives of affected patients,” commented Raghuram (Ram) Selvaraju, PhD, MBA, Chairman of Relief Holding. “I would like to warmly express my gratitude to those individuals who have been working hard to make it happen and, in particular, Pankaj Mohan, founder of Sonnet and Chairman and CEO of Sonnet Holdings.

Our initial commitment to the development of Atexakin Alfa will be aggressively pursued imposing extremely demanding timelines to reach high-end objectives, as we strongly believe in the potential of this compound to treat this underserved group of diseases that is constituted by neuropathies” added Pankaj Mohan, PhD, Chairman and CEO of Sonnet Holdings. “We are more than ever excited to deliver new therapeutic solutions to patients in need and Atexakin Alfa perfectly fits within the pipeline of earlier-stage projects that we are currently developing. I wanted to thank all of Relief Holding’s representatives for their positive and supportive commitment to getting this deal where it has ended up today.”

About RELIEF THERAPEUTICS Holding SA

Relief Holding is a company developing drugs via participation in active entities that have obtained intellectual properties through their own research activities or via in-licensing. Development activities of Relief Holding group of companies focus primarily on clinical-stage projects based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rational. Currently, Relief Holding is concentrating its efforts on developing new treatment solutions for indications related to respiratory diseases in particular COVID-19-induced ARDS.

About Sonnet BioTherapeutics, Inc.

Founded in 2011, Sonnet BioTherapeutics, Inc., now a wholly-owned subsidiary of Sonnet BioTherapeutics Holdings, Inc., is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single- or bi-specific action. Known as FHAB™ (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (“scFv”) that binds to and “hitch-hikes” on human serum albumin (“HSA") for transport to target tissues. FHAB™ is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies and vaccines.

About Chemotherapy Induced Peripheral Neuropathy

Chemotherapy Induced Peripheral Neuropathy (“CIPN”) is a progressive degeneration of nerve fibers resulting from chemotherapy. It is a debilitating condition for which there are currently no approved treatments. Symptoms of CIPN include pain, motor weakness, loss of sensory perception at the extremities and autonomous nervous system impairment. It is estimated that over 50% of cancer patients receiving chemotherapy develop CIPN and that the condition persists in over 50% of cancer survivors.

RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF.

Damien Conus, Partner, Vischer Genève Sàrl, Geneva/Switzerland, represented Relief Holding in this transaction. Raymond Felton, is Co-managing Partner / Chair of the corporate department of Greenbaum, Rowe, Smith and Davis Counselors at law from Woodbridge, New Jersey, USA, and led the legal team that represented Sonnet in this transaction.

For further information, please visit the Relief Holding’s website at www.relieftherapeutics.com or contact:

Source: RELIEF THERAPEUTICS Holding SA

Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding SA, Sonnet BioTherapeutics Holdings, Inc. and their business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding SA and/or Sonnet BioTherapeutics Holdings, Inc. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Contact information

Investor Contact
RELIEF THERAPEUTICS Holding SA
Avenue de Sécheron 15
CH-1202 Geneva
investors@relieftherapeutics.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

VR Fitness Developer FitXR Secures $7.5 Million In Series A Venture Round Led by Hiro Capital10.7.2020 08:00:00 CESTPress release

FitXR, the leading VR fitness company, today announces that it has secured $6.3m in investment funding, led by Hiro Capital, with continued support from U.S.-based BoostVC, Maveron and TenOneTen Ventures, together with an additional $1.2m in the form of an innovation loan, from Innovate UK. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200709005856/en/ Cherry Freeman, Co-Founding Partner, Hiro Capital (Photo: Business Wire) FitXR, who had previously secured $1.25 million in seed funding from investors, will use the new investment to expand its operations in Europe and North America, and to accelerate launch of several exciting new products and services for people to keep fit in Virtual Reality. The investment marks a significant show of belief in FitXR, who over the last year has grown to become one of the leaders of the VR fitness sector, with its mission to put the fun back into fitness. Its first product, the boxing rhyt

Laboratory Studies Confirm BETADINE® Antiseptic Products’ Effectiveness Against COVID-19 Virus10.7.2020 00:37:00 CESTPress release

Mundipharma today announced that laboratory testing at the Duke-NUS Medical School in Singapore, has confirmed the effectiveness of its BETADINE® antiseptic products against the novel coronavirus (SARS-CoV-2) which causes COVID-19 disease. Testing has demonstrated BETADINE’s® strong in-vitro virucidal activity, killing 99.99% of the SARS-CoV-2 virus in 30 seconds. The products subjected to testing were: BETADINE® antiseptic products, namely Solution (10% PVP-I), Skin Cleanser (7.5% PVP-I), Gargle and Mouthwash (1.0% PVP-I) and Throat Spray (0.45% PVP-I). The research has been published in the respected Infectious Disease and Therapy Journal on 08 July 2020. “These results confirm our view that BETADINE® antiseptic products, used appropriately and in conjunction with other preventative treatment options including PPE, can play a role in limiting the spread of infections, including COVID-19,” said Raman Singh, CEO Mundipharma. “It also provides the medical community as well as consumers

New Evidence Shows Morinaga Milk’s Probiotic Bifidobacterium breve A1 Improves Memory of Older Adults With Cognitive Dysfunction9.7.2020 20:00:00 CESTPress release

Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy product company and a key global probiotics manufacturer, confirmed that its proprietary probiotic strain Bifidobacterium breve A1 (a.k.a. B. breve MCC1274) is safe and effective for improving memory functions of older adults with suspected mild cognitive impairment (MCI) in a randomized, double-blind, placebo-controlled trial (RCT). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200709005032/en/ Figure 1. Changes of RBANS scores at 16 weeks from baseline. Values are indicated as mean with error bars as the standard error. **p<0.001, ***p<0.0001, inter-group difference, Student’s t-test. (Graphic: Business Wire) The new study, published recently in the Journal of Alzheimer’s Disease, has produced breakthrough results uncovering a novel promising probiotic intervention for early dementia prevention. The clinical study conducted by a clinical research orga

rf IDEAS and Ricoh Simplify Secure Access to Multifunction Printers9.7.2020 18:05:00 CESTPress release

rf IDEAS, a leading manufacturer of credential readers for authentication and logical access, today announced with Ricoh the integration of its WAVE ID® Plus dual-frequency card reader technology with Ricoh’s Smart Operation Panel (SOP), Gen 2.5. The new WAVE ID Ricoh Universal SOP Reader is the most innovative reader for secure pull-print applications with Ricoh multifunction printers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200709005764/en/ WAVE ID® Ricoh Universal SOP Reader (Photo: Business Wire) rf IDEAS and Ricoh have a proven record of working together to deliver secure workplace solutions that feature the most advanced identification and authentication capabilities. “As we continue our worldwide partnership with a leader in the print industry, we are delighted that Ricoh chose rf IDEAS to develop an innovative credential reader design that connects to its A3 multifunction devices,” said Tod Besse, senior vice

Immersive Labs Adds Tenable Co-Founder and Security Industry Veteran Jack Huffard to its Board of Directors as Demand for Improving and Measuring Cyber Talent Grows9.7.2020 17:46:00 CESTPress release

Immersive Labs, the company empowering organizations to equip, exercise, and evidence human cyber capabilities, announced Jack Huffard, a co-founder and board member of Tenable (Nasdaq: TENB) will join its board of directors to help drive growth. This comes on the heels of Immersive Labs’ recent expansion into the U.S. market, backed by Goldman Sachs and Summit Partners with $50M in financing, after four successful years of fast-growth and an impressive customer roster in the UK and the U.S. With the addition of Huffard to the board, a cybersecurity industry business leader who helped Tenable through its fast growth and successful IPO, the Immersive Labs team is well-suited for its next phase of innovation and market leadership. Huffard also currently serves as a board director for Norfolk Southern Corporation (NYSE: NSC) and is a member of the National Security Telecommunications Advisory Committee (NSTAC), helping the US government navigate pressing national security issues and stren

Jonckers Announces New CEO9.7.2020 17:08:00 CESTPress release

Jonckers, a global leader in language platform technology and multilingual solutions, today announced that its Board of Directors has appointed Silke Zschweigert as Chief Executive Officer, effective immediately. Zschweigert previously held the position of Chief Revenue Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200709005715/en/ Silke Zschweigert Newly appointed CEO of Jonckers - a global leader in language platform technology and multilingual solutions (Photo: Business Wire) “I’m very privileged to be asked by the Board to be the next CEO of this dynamic and forward-thinking company,” said Zschweigert. “The company transitioned from being a pure language service provider to an AI-driven Language Platform with a multilingual community. I look forward to scaling this capability and further developing advanced solutions creating significant value for Enterprises going global.” Zschweigert succeeds Geo Janssens who

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom